Corindus Vascular Robotics Inc (CVRS) Director Buys $35,100.00 in Stock

Corindus Vascular Robotics Inc (NYSEMKT:CVRS) Director Louis A. Cannon bought 27,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 22nd. The shares were acquired at an average cost of $1.30 per share, for a total transaction of $35,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) opened at 1.14 on Tuesday. The company’s 50-day moving average price is $0.92 and its 200 day moving average price is $0.85. The firm’s market cap is $135.69 million. Corindus Vascular Robotics Inc has a 1-year low of $0.40 and a 1-year high of $1.80.

TRADEMARK VIOLATION NOTICE: “Corindus Vascular Robotics Inc (CVRS) Director Buys $35,100.00 in Stock” was posted by Mideast Time and is the property of of Mideast Time. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.mideasttime.com/corindus-vascular-robotics-inc-cvrs-director-buys-35100-00-in-stock/1590404.html.

A hedge fund recently raised its stake in Corindus Vascular Robotics stock. State Street Corp boosted its stake in Corindus Vascular Robotics Inc (NYSEMKT:CVRS) by 0.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 566,932 shares of the company’s stock after buying an additional 4,847 shares during the period. State Street Corp owned about 0.48% of Corindus Vascular Robotics worth $395,000 at the end of the most recent reporting period.

Several equities research analysts have recently weighed in on the company. B. Riley raised Corindus Vascular Robotics to a “buy” rating and set a $3.00 price target for the company in a research note on Wednesday, March 22nd. Zacks Investment Research raised Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 17th.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.